title: HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations.
abstract: We evaluated the immunogenicity of a prime/boost vaccine strategy combining 5 lipopeptides (HIV-Lipo-5) and a recombinant modified vaccinia virus Ankara (rMVA-HIV) in cynomolgus macaques. Both of these vaccine components deliver HIV LAI Gag, Pol, and Nef antigens. Systemic and local safety was excellent in all groups. Immunization with HIV-Lipo-5 alone induced significant serum anti-HIV antibody titers which were not modified by rMVA-HIV immunization. However, induction of T-cell responses, as measured by IFNγ and IL-2 producing cells upon short-term stimulation with HIV peptide pools, required combined immunization with rMVA-HIV. Responses were preferentially observed against Gag antigen. Interestingly, HIV-Lipo-5 efficiently primed HIV induced T-cell responses upon the injection of rMVA-HIV, which may help to reduce the required number of vector injections. Our results provide a rationale for the use of a strategy involving HIV-Lipo-5 priming followed by rMVA-HIV booster immunization as a prophylactic or therapeutic vaccine approach against HIV infection and AIDS.
authors.affiliation: CEA, Division of Immuno-Virology, IDMIT Center, iMETI/DSV, Fontenay-aux-Roses, France; UMR-1184, Université Paris Sud 11, Orsay, France; Vaccine Research Institute (VRI), Créteil, France.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Dereuddre-Bosquet
authors.affiliation: CEA, Division of Immuno-Virology, IDMIT Center, iMETI/DSV, Fontenay-aux-Roses, France; UMR-1184, Université Paris Sud 11, Orsay, France; Vaccine Research Institute (VRI), Créteil, France.
authors.forename: Marie-Laurence
authors.initials: ML
authors.lastname: Baron
authors.affiliation: CEA, Division of Immuno-Virology, IDMIT Center, iMETI/DSV, Fontenay-aux-Roses, France; UMR-1184, Université Paris Sud 11, Orsay, France; Vaccine Research Institute (VRI), Créteil, France.
authors.forename: Vanessa
authors.initials: V
authors.lastname: Contreras
authors.affiliation: CEA, Division of Immuno-Virology, IDMIT Center, iMETI/DSV, Fontenay-aux-Roses, France; UMR-1184, Université Paris Sud 11, Orsay, France; Vaccine Research Institute (VRI), Créteil, France.
authors.forename: Leslie
authors.initials: L
authors.lastname: Gosse
authors.affiliation: CEA, Division of Immuno-Virology, IDMIT Center, iMETI/DSV, Fontenay-aux-Roses, France; UMR-1184, Université Paris Sud 11, Orsay, France; Vaccine Research Institute (VRI), Créteil, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Mangeot
authors.affiliation: CEA, Division of Immuno-Virology, IDMIT Center, iMETI/DSV, Fontenay-aux-Roses, France; UMR-1184, Université Paris Sud 11, Orsay, France; Vaccine Research Institute (VRI), Créteil, France; INSERM, Paris, France.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Martinon
authors.affiliation: Bertin Pharma, Montigny-Le-Bretonneux, France.
authors.forename: Rahima
authors.initials: R
authors.lastname: Yousfi
authors.affiliation: Bertin Pharma, Montigny-Le-Bretonneux, France.
authors.forename: Pascal
authors.initials: P
authors.lastname: Clayette
authors.affiliation: Vaccine Research Institute (VRI), Créteil, France; INSERM, Paris, France; INSERM, Unite U955, Créteil F-94010, France; Université Paris-Est, Faculté de Médecine, Hôpital Albert-Chenevier, Créteil F-94010, France; Hôpital Henri-Mondor, Service d'Immunologie clinique, UMR-S 955, Créteil F-94010, France.
authors.forename: Yves
authors.initials: Y
authors.lastname: Levy
authors.affiliation: CEA, Division of Immuno-Virology, IDMIT Center, iMETI/DSV, Fontenay-aux-Roses, France; UMR-1184, Université Paris Sud 11, Orsay, France; Vaccine Research Institute (VRI), Créteil, France. Electronic address: roger.le-grand@cea.fr.
authors.forename: Roger
authors.initials: R
authors.lastname: Le Grand
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology*; D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D016207:Cytokines / Q000097:blood / Q000276:immunology; D058501:Enzyme-Linked Immunospot Assay; D015483:HIV Antibodies / Q000097:blood* / Q000276:immunology; D015488:HIV Antigens / Q000008:administration & dosage / Q000276:immunology*; D007117:Immunization, Secondary; D007371:Interferon-gamma / Q000276:immunology; D007376:Interleukin-2 / Q000276:immunology; D055666:Lipopeptides / Q000276:immunology*; D008252:Macaca fascicularis; D013601:T-Lymphocytes / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics*
chemical_list: D016915:AIDS Vaccines; D016207:Cytokines; D015483:HIV Antibodies; D015488:HIV Antigens; D007376:Interleukin-2; D055666:Lipopeptides; D014614:Vaccines, Synthetic; D007371:Interferon-gamma
keywords: HIV; Lipopeptide; MVA; NHP